SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-24-011806
Filing Date
2024-08-12
Accepted
2024-08-12 08:35:29
Documents
44
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q apre-20240630x10q.htm   iXBRL 10-Q 1447794
2 EX-31.1 apre-20240630xex31d1.htm EX-31.1 10251
3 EX-31.2 apre-20240630xex31d2.htm EX-31.2 10537
4 EX-32.1 apre-20240630xex32d1.htm EX-32.1 6698
5 EX-32.2 apre-20240630xex32d2.htm EX-32.2 6712
  Complete submission text file 0001558370-24-011806.txt   3912164

Data Files

Seq Description Document Type Size
6 EX-101.SCH apre-20240630.xsd EX-101.SCH 25195
7 EX-101.CAL apre-20240630_cal.xml EX-101.CAL 28600
8 EX-101.DEF apre-20240630_def.xml EX-101.DEF 92683
9 EX-101.LAB apre-20240630_lab.xml EX-101.LAB 233410
10 EX-101.PRE apre-20240630_pre.xml EX-101.PRE 156136
47 EXTRACTED XBRL INSTANCE DOCUMENT apre-20240630x10q_htm.xml XML 299874
Mailing Address 3805 OLD EASTON ROAD DOYLESTOWN PA 18902
Business Address 3805 OLD EASTON ROAD DOYLESTOWN PA 18902 617-463-9385
Aprea Therapeutics, Inc. (Filer) CIK: 0001781983 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39069 | Film No.: 241195010
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)